CDC Level 1 Travel Notice: Global Dengue Risk

Global Dengue — CDC Level 1 (Practice Usual Precautions)

Published: 2 October 2026 · Source: CDC Travelers' Health

What the notice says

The CDC reports that dengue remains a year-round risk in many tropical and subtropical regions, with larger outbreaks typically recurring every 2–5 years. A Level 1 notice is the agency's lowest tier and asks travelers to practice usual precautions rather than to change or cancel plans.

Destinations named in the current notice include: Colombia, Vietnam, Maldives, Bolivia, Cambodia, Kenya, Malaysia, Sri Lanka, Bangladesh, Costa Rica, Marshall Islands, Vanuatu, Cuba, Ecuador (including the Galápagos Islands), and Panama. Lists are updated frequently, so travelers should check the CDC page for their specific destination before departure.

Background information

  • Dengue viruses are spread by Aedes mosquitoes, which bite mainly during daylight hours, peaking in early morning and late afternoon — unlike malaria vectors.
  • These mosquitoes breed in small volumes of standing water around human dwellings, so risk exists in urban and resort areas, not only rural ones.
  • Most infections are mild or without symptoms. Reported features include fever, headache, eye pain, muscle and joint aches, nausea, and rash, typically beginning 4–10 days after a bite.
  • Public-health authorities emphasize that warning signs — severe abdominal pain, persistent vomiting, bleeding from the gums or nose, blood in vomit or stool, or extreme lethargy — require immediate in-person medical assessment.
  • There are four dengue virus serotypes; a prior infection does not protect against the others, and second infections carry a higher risk of severe disease.
  • Bite-prevention measures cited by CDC include EPA-registered repellents, long sleeves and trousers, permethrin-treated clothing, and air-conditioned or screened accommodation.
  • Vaccine availability and eligibility differ by country and by prior-infection status; this is a clinician-assessed decision, not an over-the-counter choice.

Pharmacist's note: Two points are worth flagging from a pharmaceutical-sciences perspective. First, self-medication choices matter in dengue-endemic areas — several common over-the-counter analgesics and anti-inflammatories are specifically discussed in dengue guidance because of bleeding and platelet considerations, so clarify your options with a pharmacist or physician before you travel rather than at a pharmacy counter abroad. Second, repellent effectiveness is driven by active ingredient and concentration, which determine duration rather than strength; read the label for reapplication intervals, and if you also use sunscreen, apply sunscreen first. Travelers on anticoagulants, antiplatelets, or immunosuppressants should seek pre-travel advice. This summary is general public information and not individual medical advice — any fever during or within two weeks after travel warrants prompt professional evaluation.

Primary sources

PharmTrip may include promotional content. Products and services are independently evaluated by a licensed pharmacist and rankings are never altered by advertiser requests. Information reflects what was current at the time of writing — please verify the latest terms on each provider's official site.